Hansa Biopharma AB (publ)

OM:HNSA Stock Report

Market Cap: SEK 2.4b

Hansa Biopharma Management

Management criteria checks 2/4

Hansa Biopharma's CEO is Søren Tulstrup, appointed in Mar 2018, has a tenure of 6.83 years. total yearly compensation is SEK27.51M, comprised of 30.7% salary and 69.3% bonuses, including company stock and options. directly owns 0.085% of the company’s shares, worth SEK2.01M. The average tenure of the management team and the board of directors is 4.7 years and 3.7 years respectively.

Key information

Søren Tulstrup

Chief executive officer

SEK 27.5m

Total compensation

CEO salary percentage30.7%
CEO tenure6.8yrs
CEO ownership0.08%
Management average tenure4.7yrs
Board average tenure3.7yrs

Recent management updates

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Jun 21
Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Recent updates

Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Dec 22
Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks

Nov 07
It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Oct 20
Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Aug 24
Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Jul 23
Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Jul 21
Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Jun 21
Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

May 21
Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Apr 05
Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07
Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Dec 28
Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Oct 13
Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Sep 22
Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

May 31
Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Apr 03
Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Feb 06
Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Feb 01
Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

CEO Compensation Analysis

How has Søren Tulstrup's remuneration changed compared to Hansa Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 655m

Jun 30 2024n/an/a

-SEK 802m

Mar 31 2024n/an/a

-SEK 845m

Dec 31 2023SEK 28mSEK 8m

-SEK 832m

Sep 30 2023n/an/a

-SEK 856m

Jun 30 2023n/an/a

-SEK 759m

Mar 31 2023n/an/a

-SEK 678m

Dec 31 2022SEK 26mSEK 8m

-SEK 611m

Sep 30 2022n/an/a

-SEK 626m

Jun 30 2022n/an/a

-SEK 620m

Mar 31 2022n/an/a

-SEK 583m

Dec 31 2021SEK 26mSEK 7m

-SEK 548m

Sep 30 2021n/an/a

-SEK 491m

Jun 30 2021n/an/a

-SEK 465m

Mar 31 2021n/an/a

-SEK 431m

Dec 31 2020SEK 21mSEK 6m

-SEK 421m

Sep 30 2020n/an/a

-SEK 426m

Jun 30 2020n/an/a

-SEK 398m

Mar 31 2020n/an/a

-SEK 381m

Dec 31 2019SEK 11mSEK 5m

-SEK 360m

Sep 30 2019n/an/a

-SEK 330m

Jun 30 2019n/an/a

-SEK 298m

Mar 31 2019n/an/a

-SEK 274m

Dec 31 2018SEK 8mSEK 4m

-SEK 248m

Compensation vs Market: Søren's total compensation ($USD2.47M) is above average for companies of similar size in the Swedish market ($USD450.84K).

Compensation vs Earnings: Søren's compensation has increased whilst the company is unprofitable.

CEO

Søren Tulstrup (59 yo)

6.8yrs

Tenure

SEK 27,505,000

Compensation

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...

Leadership Team

NamePositionTenureCompensationOwnership
Søren Tulstrup
President & CEO6.8yrsSEK 27.51m0.085%
SEK 2.0m
C. Ballantyne
Chief Financial Officerless than a yearno datano data
Hitto Kaufmann
Chief Scientific and R&D Officer1.1yrsno datano data
Eva-Maria Joed
Vice President of Finance & Administration5.7yrsno datano data
Klaus Sindahl
VP & Head of Investor Relationsno datano datano data
Anne Lanner
Senior VP & Chief Human Resources Officer6yrsno datano data
Emanuel Björne
VP & Head of Business Developmentno datano datano data
Lena Winstedt
Head of Scienceno datano datano data
Vincenza Nigro
VP & Head of Medical Affairsno datano datano data
Magnus Korsgren
VP & Head of Research and Development3.8yrsno datano data

4.7yrs

Average Tenure

55yo

Average Age

Experienced Management: HNSA's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Florian Nicolas Reinaud
Directorless than a yearno datano data
Anders Pedersen
Independent Director6.7yrsSEK 413.00kno data
Mats Blom
Independent Director5.7yrsSEK 493.00kno data
Peter Nicklin
Independent Chairman of the Board2.6yrsSEK 1.14m0.036%
SEK 856.6k
Eva Nilsagard
Independent Director5.7yrsSEK 591.00kno data
Hilary Malone
Independent Director3.7yrsSEK 725.00kno data
Gunnar Tufveson
Chairman of European Medical Advisory Board in Transplantationno datano datano data
Kathryn Wood
Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantationno datano datano data
Christophe Legendre
Member of European Medical Advisory Board in Transplantationno datano datano data
Stanley Jordan
Chairman of US Medical Advisory Board in Transplantationno datano datano data
Robert Montgomery
Member of US Medical Advisory Board in Transplantationno datano datano data
Jonas Wikstrom
Directorless than a yearno datano data

3.7yrs

Average Tenure

59.5yo

Average Age

Experienced Board: HNSA's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 22:28
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hansa Biopharma AB (publ) is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Christian LeeABG Sundal Collier Sponsored
Madhu KumarB. Riley Securities, Inc.